SCHEMBL2925430

SCHEMBL2925430

COc1ccc(-c2nc3sc4c(c3c(=O)n2Cc2ccccc2)CCCC4=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
GAA P10253 2/20 0.51
RECQL P46063 1/20 0.51
MAPT P10636 3/20 0.47
POLB P06746 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 3/20 0.47
TP53 P04637 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
BLM P54132 1/20 0.47
KDM4E B2RXH2 3/20 0.46
LMNA P02545 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
CNR2 P34972 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922258 0.90 POLB (0.53) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2925132 0.90 POLB (0.45) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2924913 0.87 TP53 (0.60) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2923793 0.86 HSD11B1 (0.48) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL2925635 0.85 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2917209 0.84 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2916941 0.84 POLB (0.56) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL13869616 0.83 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AGAARECQL
SCHEMBL2921750 0.81 POLB (0.50) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL2926159 0.80 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1635839-B1 BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY ABBOTT HEALTHCARE PRODUCTS BV (NL) 2010-09-01 EP disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7524853-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2009-04-28 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 US disclosed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885MEN1 2028/4885KMT2A 2945/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885MEN1 2028/4885KMT2A 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.